A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
NCT ID: NCT02757768
Last Updated: 2024-11-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
715 participants
INTERVENTIONAL
2016-06-13
2018-09-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
NCT02656173
Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.
NCT02279615
Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP
NCT03632772
Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
NCT01018511
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
NCT00771394
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If participants met all entry criteria at the end of the tamsulosin hydrochloride run-in period, participants were randomized to 1 of 2 treatment groups (mirabegron or placebo) for 12 weeks of treatment in addition to the continuation of tamsulosin hydrochloride 0.4 mg QD. Those participants randomized to Mirabegron started at 25 mg and increased to 50 mg after 4 weeks. Those participants randomized to placebo started blinded product matched to the mirabegron 25 mg tablet and increased to blinded product matched to 50 mirabegron after 4 weeks. Once a participant increased dose, the participant remained on that dose for the remainder of the study unless for safety reasons was required to discontinue study drug.
A training diary was completed in the first 2 weeks of the tamsulosin hydrochloride run-in period. During this evaluation period at least one telephone contact took place with the participant. Diaries were completed at home, using the electronic patient-reported outcome (ePRO) device, for 3 consecutive days prior to each visit: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4), and Week 12/End of Treatment (Visit 5). Site staff contacted the participant approximately 7 days prior to the scheduled visit to remind the participant to complete the electronic diary, review completion instruction and review changes to concomitant medications and adverse events (if applicable).
Three days before Visits 2 (Baseline), 3 (Week 4), 4 (Week 8), and 5 (Week 12), participants completed a 3-day diary, using the ePRO device in which the participant recorded micturition frequency, urgency (PPIUS), incontinence and volume voided. In addition, the diary captured morning and evening blood pressure and pulse rate measurements via Home Blood Pressure Monitoring (HBPM). At Visit 1, International Prostate Symptom Score (IPSS) was completed. At Visits 2, 3, 4, and 5, participants completed the IPSS, EQ-5D-5L, OAB-q, PPBC, and TS-VAS. Maximum urinary flow (Qmax) was measured at Visit 1 (Screening/tamsulosin hydrochloride run-in) and Visit 5 (Week 12/End of Treatment). Post-void residual volume (PVR) was assessed at Screening/tamsulosin hydrochloride run-in (Visit 1), Baseline (Visit 2) and at Week 4 (Visit 3), Week 8 (Visit 4), and Week 12/End of Treatment (Visit 5). A follow-up phone call (Visit 6) was conducted 4-weeks after End of Treatment (Visit 5). Total study participation was approximately 20 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mirabegron
Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study.
Mirabegron
Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
Tamsulosin Hydrochloride
Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Placebo
Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study.
Placebo
Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
Tamsulosin Hydrochloride
Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mirabegron
Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
Placebo
Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
Tamsulosin Hydrochloride
Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has symptoms of OAB (urinary frequency and urgency with or without incontinence) for ≥3 months prior to Screening.
* Subject has an International Prostate Symptom Score (IPSS) score ≥8.
* Subject has Prostate-Specific Antigen (PSA) \<4 ng/mL or ≥4 but \< 10 ng/mL with a prostate biopsy that is negative for cancer in the past 2 years.
* Subject is willing and able to complete the 3-day diary (including urine volumes, vital signs measurements), and Quality of Life questionnaires.
* Subject and the subject's spouses/partners who are of childbearing potential must be using a highly effective birth control, which includes established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS). Birth control must be practiced from Screening and continue throughout the study and for 30 days after the final study drug administration. In addition, sperm donation will not be allowed throughout the study and for 30 days after the final study drug administration.
* Subject agrees not to participate in another interventional study while on treatment.
* Subject must experience an average of 8 or more micturitions per day over the 3-day diary period.
* Subject must experience an average of 2 episodes of urgency per day (grade 3 or 4) over the 3-diary period
Exclusion Criteria
* Subject has maximum urinary flow (Qmax) \<5.0 mL/second with a minimum voided volume of 125 mL.
* Subject has hematuria \>3 rbc/hpf that has not been fully evaluated.
* Subject has evidence of Urinary Tract Infection (UTI). Urine culture and sensitivity will be performed for positive leukocytes, nitrites, or turbidity and will be confirmed with a culture greater than 100,000 cfu/mL. If a subject has a UTI, at Screening (Visit 1) the subject may be rescreened after successful treatment of the UTI (confirmed by a laboratory result of negative urine culture).
* Subject has neurogenic bladder (spinal cord injury, multiple sclerosis, Parkinson's, etc.).
* Subject has diabetic neuropathy.
* Previous open, robotic or minimally invasive prostate surgery (including transurethral procedures). Planned (scheduled) pelvic or prostate surgery during the study period.
* Planned (scheduled) cataract surgery.
* Subject with significant stress incontinence
* Subject with clinically significant bladder outlet obstruction.
* Subject has an indwelling catheter or practices intermittent self-catheterization.
* Subject has experienced 3 or more episodes of recurrent urinary tract infection within the last 12 months.
* Subject has a symptomatic urinary tract infection, prostatitis, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs (i.e., within the confines of the pelvis including the bladder, prostate and rectum; organs of the lower gastrointestinal tract are not necessarily considered pelvic organs such as the distal ascending colon, the full transverse colon and proximal portion of the descending colon are in the abdomen).
* Subject has received intravesical injection in the past 12 months with botulinum toxin, resiniferatoxin, or capsaicin.
* Subject has ever received electro-stimulation therapy for OAB (e.g. sacral nerve stimulation or Percutaneous Tibial Nerve Stimulation \[PTNS\]).
* Subject began or has changed a bladder training program or pelvic floor exercises less than 30 days prior to Screening.
* Subject has postural hypotension or syncope or postural orthostatic tachycardia.
* Subject has moderate or severe hepatic impairment defined as Child-Pugh Class B or C.
* Subject has severe renal impairment defined as estimated creatinine clearance less than 29 mL/min/1.73 m2 as determined by hospital laboratory calculation of eGFR. A subject with End Stage Renal Disease (ESRD) or undergoing dialysis is also not a candidate for the study.
* Subject has severe uncontrolled hypertension, which is defined as a sitting systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg.
* Subject has baseline resting pulse rate \<60 BPM or \>90 BPM.
* Subject has evidence of QT prolongation on Screening (Visit 1) or Baseline (Visit 2) electrocardiogram (ECG) defined as QTcF \>450 msec.
* Subject has any clinically significant ECG abnormality.
* Subject has AST or ALT \>2x upper limit of normal (ULN), or γ-GT \>3x ULN and considered clinically significant.
* Subject has a hypersensitivity to any components of mirabegron, tamsulosin hydrochloride, or any of the inactive ingredients.
* Subject has a history of angioedema.
* Subject has any clinical significant condition which makes the subject unsuitable for study participation.
* Subject has been treated with an experimental device within 28 days or received an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to Screening.
* Subject has a concurrent malignancy or history of any malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.
* Subject has ongoing alcohol and/or drug abuse.
* Subject is using prohibited medications within 30 days prior to Screening (Visit 1) through Follow-Up Phone Call (Visit 6).
* Subject has stopped, started or changed the dose of a restricted medication within the 30 days prior to Screening (Visit 1) through Follow-Up Phone Call (Visit 6)
* Subject has participated in an interventional trial within 30 days prior to Screening (Visit 1).
* Subject is involved in the conduct of the study as an employee of the Astellas group, third party associated with the study, or the study site team.
* Subject has previously received mirabegron in the 6 months prior to Screening (Visit 1).
* Subject was non-compliant during the 4-week tamsulosin hydrochloride run-in period, defined as taking less than 80% or greater than 120% of study medication.
* Subject had an average total daily urine volume \>3000 mL as recorded in the 3-day diary.
40 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Global Development, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Global Development, Inc., Medical Affairs, Americas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site US01009
Homewood, Alabama, United States
Site US01005
Huntsville, Alabama, United States
Site US01012
Anchorage, Alaska, United States
Site US01070
Hawaiian Gardens, California, United States
Site US01081
Los Angeles, California, United States
Site US01021
Murrieta, California, United States
Site US01068
San Diego, California, United States
Site US01064
Valley Village, California, United States
Site US01097
Englewood, Colorado, United States
Site US01026
Pompano Beach, Florida, United States
Site US01025
St. Petersburg, Florida, United States
Site US01027
Wellington, Florida, United States
Site US01034
West Des Moines, Iowa, United States
Site US01094
Shreveport, Louisiana, United States
Site US01041
Baltimore, Maryland, United States
Site US01016
Boston, Massachusetts, United States
Site US01003
Watertown, Massachusetts, United States
Site US01060
Kansas City, Missouri, United States
Site US01067
Billings, Montana, United States
Site US01061
Omaha, Nebraska, United States
Site US01029
Edison, New Jersey, United States
Site US01031
Albuquerque, New Mexico, United States
Site US01015
Garden City, New York, United States
Site US01019
Plainview, New York, United States
Site US01069
Cary, North Carolina, United States
Site US01079
Maiden, North Carolina, United States
Site US01072
Bristol, Tennessee, United States
Site US01042
Clarksville, Tennessee, United States
Site US01056
Knoxville, Tennessee, United States
Site US01075
Knoxville, Tennessee, United States
Site US01078
Knoxville, Tennessee, United States
Site US01063
Newport News, Virginia, United States
Site CA15008
Calgary, Alberta, Canada
Site CA15003
Barrie, Ontario, Canada
Site CA15001
Brampton, Ontario, Canada
Site CA15005
Toronto, Ontario, Canada
Site CA15011
Québec, Quebec, Canada
Site CA15002
Sherbrooke, Quebec, Canada
Site CA15009
Sherbrooke, Quebec, Canada
Site CA15014
Victoriaville, Quebec, Canada
Site CZ42004
Benešov, , Czechia
Site CZ42006
Domažlice, , Czechia
Site CZ42005
Prague, , Czechia
Site CZ42003
Prague, , Czechia
Site CZ42001
Sternberk, , Czechia
Site FR33004
Colmar, , France
Site FR33002
Pierre-Bénite, , France
Site DE49002
Duisburg, , Germany
Site DE49003
Eisleben Lutherstadt, , Germany
Site DE49001
Hagenow, , Germany
Site DE49006
Halle, , Germany
Site DE49004
Hamburg, , Germany
Site DE49005
Hettstedt, , Germany
Site DE49007
Sangerhausen, , Germany
Site IT39002
Avellino, , Italy
Site IT39003
Catanzaro, , Italy
Site IT39010
Chieti, , Italy
Site IT39004
Florence, , Italy
Site IT39005
Latina, , Italy
Site IT39006
Pisa, , Italy
Site IT39001
Treviglio, , Italy
Site IT39008
Vasto, , Italy
Site PL48006
Katowice, , Poland
Site PL48001
Piaseczno, , Poland
Site PL48004
Warsaw, , Poland
Site PL48005
Wroclaw, , Poland
Site PL48007
Wroclaw, , Poland
Site ES34007
Barcelona, , Spain
Site ES34009
Lugo, , Spain
Site ES34001
Madrid, , Spain
Site ES34003
Miranda de Ebro, , Spain
Site ES34002
Seville, , Spain
Site ES34006
Valencia, , Spain
Site ES34004
Vigo, , Spain
Site GB44005
Bristol, , United Kingdom
Site GB44011
Bristol, , United Kingdom
Site GB44004
Newcastle upon Tyne, , United Kingdom
Site GB44002
Reading, , United Kingdom
Site GB44006
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on the Astellas Clinical Study Results website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-004036-36
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
178-MA-1008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.